Álvarez-Román MT, Cuervo-Arango I, Pérez-Santamarina R, Poveda JL, Romero JA, Santamaría A, Trillo-Mata JL, Tort M, Badia X. Determining the value contribution of emicizumab (Hemlibra®) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis. Grhta [Internet]. 2019 Oct. 8 [cited 2024 Nov. 21];6(1). Available from: https://journals.aboutscience.eu/index.php/grhta/article/view/452